Lexaria Bioscience (LEXX) Free Cash Flow Growth (1y) (2011 - 2026)
Lexaria Bioscience (LEXX) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
88.70% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-15.72% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
66.37% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Lexaria Bioscience |
7.49 Mn |
1.97 Mn |
20,000.00 |
-47.19% |
| Date | Value |
|---|
| Feb 28, 2026 |
-47.19% |
| Nov 30, 2025 |
64.22% |
| Aug 31, 2025 |
-36.59% |
| May 31, 2025 |
-183.08% |
| Feb 28, 2025 |
-141.75% |
| Nov 30, 2024 |
-132.78% |
| Aug 31, 2024 |
-19.30% |
| May 31, 2024 |
29.11% |
| Feb 29, 2024 |
50.09% |
| Nov 30, 2023 |
6.65% |
| Aug 31, 2023 |
-37.83% |
| May 31, 2023 |
-41.08% |
| Feb 28, 2023 |
2.80% |
| Nov 30, 2022 |
-4.73% |
| Aug 31, 2022 |
-5.79% |
| May 31, 2022 |
-9.44% |
| Feb 28, 2022 |
-100.24% |
| Nov 30, 2021 |
-49.31% |
| Aug 31, 2021 |
-73.96% |
| May 31, 2021 |
-72.52% |
